Notice of Change to the Application Due Date on PAR-19-357, "Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01 Clinical Trial Not Allowed)"

Notice Number: NOT-AI-19-069

Key Dates
Release Date: September 18, 2019

Related Announcements
PAR-19-357

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this Notice is to alert potential applicants to a change in the application due date(s) for Funding Opportunity Announcement (FOA) PAR-19-357 , "Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01 Clinical Trial Not Allowed)".

Part 1: Overview Information
Key Dates

Current Date:

Application Due Date(s): Only accepting applications for the AIDS Application Due Dates listed below.

Revised Date:

Application Due Date(s): January 8, 2020; January 8, 2021; January 10, 2022

All applications are due, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Daniel Frank, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-761-6256
Email: Daniel.Frank@nih.gov